XTRA:MRKPharmaceuticals
Merck KGaA (XTRA:MRK) Pushes Into Precision Cardiology On A Deal That Leaves Valuation In Focus
Merck KGaA (XTRA:MRK) has agreed to fund and potentially acquire Saturnus Bio, a Versant Ventures founded biotech, in a research stage collaboration focused on rare genetic cardiomyopathies, a field currently lacking approved targeted therapies.
See our latest analysis for Merck KGaA.
Against this backdrop of new cardiology ambitions, Merck KGaA’s share price has gained momentum, with a 31.06% 3 month share price return and a 29.51% 1 year total shareholder return, while 3 and 5 year total...